|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 124.3 USD | -9.91% |
|
-4.87% | +0.20% |
| Apr. 26 | Wall Street: the worst week of 2024 is followed by the best | CF |
| Apr. 26 | Morgan Stanley Adjusts DexCom's Price Target to $132 From $122 | MT |
DexCom, Inc. reported earnings results for the full year ended December 31, 2021. For the full year, the company reported sales was USD 2,448.5 million compared to USD 1,926.7 million a year ago. Net income was USD 154.7 million compared to USD 493.6 million a year ago.
Basic earnings per share from continuing operations was USD 0.4 compared to USD 1.3075 a year ago. Diluted earnings per share from continuing operations was USD 0.3875 compared to USD 1.265 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +0.20% | 54.66B | |
| -2.31% | 185B | |
| -3.20% | 105B | |
| -5.04% | 66.59B | |
| +17.29% | 47.78B | |
| +4.06% | 41.26B | |
| +2.36% | 26.95B | |
| +2.07% | 26.37B | |
| +12.96% | 24.8B | |
| -1.93% | 24.6B |
DEXCOM, INC. 
